Responses
Regular and young investigator award abstracts
Clinical trials in progress
377 AGEN2373 is a CD137 agonist antibody designed to leverage optimal CD137 and FcγR co-targeting to promote antitumor immunologic effects
Compose a Response to This Article
Other responses
No responses have been published for this article.
